November 4, 2026

To Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	To The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir / Madam,

Sub: Transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company.

We would like to inform you that a proposal to transfer ownership of Auro Pharma LLC, Russia, from Auro Active Pharma Private Limited to Auropharm Overseas Limited, wholly owned subsidiaries of the Company has been approved by the board of directors of the respective companies, and also the Company in its meeting held today, November 4, 2026.

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations, is attached as Annexure.

The Board meeting commenced at 4:15 p.m and concluded at 6:00p.m.

Please take the information on record.

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.04 19:33:08 +05'30'

B. Adi Reddy
Company Secretary

Enclosures: as above

Annexure

<table>
<tr><td>a</td><td>Name of the target entity, details in brief such as size, turnover etc.;</td><td>Auro Pharma LLC, Russia (“Auro Pharma”), a step-down subsidiary of the Company in which Auroactive Pharma Private Limited (“Auroactive Pharma”), a wholly owned subsidiary of the Company, is holding 100% stake.

Transfer of entire 100% stake of Auro Pharma from Auroactive Pharma to Auropharm Overseas Limited (“Auropharm Overseas”), a wholly owned subsidiary of the Company.

The turnover of Auro Pharma, Auroactive Pharma and Auropharm Overseas for the financial year ended March 31st 2026 is as under:

<table>
<tr><td>Name of the company</td><td>Turnover for FY 2026 (INR million)</td></tr>
<tr><td>Auro Pharma LLC</td><td>Nil</td></tr>
<tr><td>Auroactive Pharma Pvt. Ltd.</td><td>701.3</td></tr>
<tr><td>Auropharm Overseas Ltd.</td><td>Nil</td></tr>
</table>
</td></tr>
<tr><td>b</td><td>Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;</td><td>Auro Pharma, Auroactive Pharma and Auropharm Overseas are wholly owned subsidiaries (directly/indirectly) of the Company and related parties to each other. The transaction is undertaken at an arm’s length price.

It may be noted that since the transaction is between two wholly owned subsidiaries of the Company, it is exempt from the applicability of provisions of Regulations 23(2), (3) and (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.</td></tr>
<tr><td>c</td><td>Industry to which the entity being acquired belongs;</td><td>Manufacturing / marketing of pharmaceutical products.</td></tr>
<tr><td>d</td><td>Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);</td><td>The proposed share transfer is undertaken as part of an internal reorganization exercise to streamline the holdings of the Russian subsidiary within the group companies.</td></tr>
<tr><td>e</td><td>Brief details of any governmental or regulatory</td><td>No governmental or regulatory approvals required.</td></tr>
</table>

<table>
<tr><td></td><td>approvals required for the acquisition;</td><td></td></tr>
<tr><td>f</td><td>Indicative time period for completion of the acquisition;</td><td>60-90 days subject to customary corporate and transfer formalities.</td></tr>
<tr><td>g</td><td>Consideration - whether cash consideration or share swap or any other form and details of the same;</td><td>Cash consideration of ~INR 29 cr. subject to adjustments, as agreed between the Parties, as on the date of transfer.</td></tr>
<tr><td>h</td><td>Cost of acquisition and/or the price at which the shares are acquired;</td><td>INR 29 crores</td></tr>
<tr><td>i</td><td>Percentage of shareholding / control acquired and / or number of shares acquired;</td><td>100%</td></tr>
<tr><td>j</td><td>Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);</td><td>Auro Pharma is a step-down subsidiary of the Company incorporated on July 24, 2023, in Russia for manufacturing and marketing pharmaceutical products.

Turnover of Auro Pharma for the last 3 years

<table><tr><th>Year</th><th>Turnover (Rs. in million)</th></tr><tr><td>2025-26</td><td>Nil</td></tr><tr><td>2024-25</td><td>Nil</td></tr><tr><td>2023-24</td><td>Nil</td></tr></table></td></tr>
</table>

Digitally signed by ADI REDDY BADDIGAM
Date: 2026.11.04 19:33:34 +05'30'